IC PHARMA
ActiveSummary
IC PHARMA has been active since 2014 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €500,272 and a net result of €128,641. Equity has been growing by about 12% per year since 2019. Its solvency ranks better than 18% of 6,178 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
Overview
Overview
Official details
Source: KBO- Status
- Active since 26-11-2014 Normal situation
- Activity
- Wholesale of pharmaceutical and medical goods NACE 46460
- Joint committee
- 200 Aanvullend Paritair Comité voor de bedienden · annual accounts 30-06-2024
- Establishment unit
- 2.359.997.627 1480 Tubize, since 01-05-2024
- Financial year end
- 30 June
- Peppol
- Reachable since 06-11-2025
Board and ownership
Board
- INTERCONCEPT SRLDirector · since 10-10-2019
- LE GALL TangieDirector · since 10-10-2019
Shareholders
- INTERCONCEPT98.92%· score 8430-06-2025 annual accounts of INTERCONCEPT
- Holdings
- Shares in 3 companies including IC PHARMA VIETNAM and SILVERSTONE SCI
Financial position
- Bankruptcy probabilitywithin 12 months
- 0.3%
Annual accounts to 30-06-2025
- Gross margin
- €434,555
- ▲ 3.5%
- Turnover
- ≈ €2.2m
- estimated
- Profit
- €128,641
- ▼ 16.3%
- Equity
- €500,272
- ▲ 1.8%
- Total assets
- €3.2m
- ▲ 0.9%
- Employees on 30-06-2025
- 3
- =
Score breakdownraises riskEquity €500,272 (15.8% of total assets)lowers riskFigures for financial year 2025 (filed on 28-01-2026)Size: 2.9 FTE, total assets €3.2mFounded in 2014Show the evidence
Checked score
Score 2025
85
/ 100
Excellent
Probability in this band: under 0.55%
Financially stronger than 38% of micro companies in wholesale trade (NACE 46)
Financial strength · tick: 2024
Weak
Solvency
41=
equity 15.8% of total assets
Liquidity
14-2
short-term debt 84.2% · cash 8.4%
Profitability
74-1
return on assets 4.1%
Bankruptcy probability within 12 months
0.3%
Very low
0%0.5%1.5%4%10%≥ 25%
About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 1.6%
01-2025: 1.9%▲ +0.3 percentage points vs 12-2024
02-2025: 2.5%▲ +0.6 percentage points vs 01-2025highest value
03-2025: 0.4%▼ -2.1 percentage points vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025
06-2025: 0.4%● unchanged vs 05-2025
07-2025: 0.4%● unchanged vs 06-2025
08-2025: 0.4%● unchanged vs 07-2025
09-2025: 0.4%● unchanged vs 08-2025
10-2025: 0.5%▲ +0.1 percentage points vs 09-2025
11-2025: 0.7%▲ +0.2 percentage points vs 10-2025
12-2025: 1.0%▲ +0.3 percentage points vs 11-2025
01-2026: 1.1%▲ +0.1 percentage points vs 12-2025
02-2026: 0.4%▼ -0.7 percentage points vs 01-2026
03-2026: 0.4%● unchanged vs 02-2026
04-2026: 0.4%● unchanged vs 03-2026
05-2026: 0.4%● unchanged vs 04-2026
06-2026: 0.4%● unchanged vs 05-2026
07-2026: 0.2%▼ -0.2 percentage points vs 06-2026lowest value
08-2026: 0.2%● unchanged vs 07-2026
09-2026: 0.2%● unchanged vs 08-2026
10-2026: 0.3%▲ +0.1 percentage points vs 09-2026
11-2026: 0.3%● unchanged vs 10-2026
Credit of up to €40,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.15 (1.16 in 2024), below the usual 1.5. Short-term debt is 84.2% and cash 8.4% of total assets. 84.2% of the assets are financed with debt and provisions.
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 46, micro). It does better than 28% of them on solvency, 14% on liquidity, 61% on profitability and 47% on growth.
The bankruptcy probability was computed on 03-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 18% of 6178 sector peers (2025).
NBB · sector comparisonPosition among 6178 sector peers
Solvency
better than 18%
← weakest
strongest →
neutral · Latest accounts filed on time
The financial year that closed on 30-06-2025 was due by 31-01-2026 and was filed on 28-01-2026, 3 days ahead of the deadline.
NBB · 10 filingsDeviation from the deadline
2025
3 days early
2024
28 days late
2023
2 days early
2022
13 days late
2021
32 days early
2020
28 days late
2019
1 day early
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 4 days after the deadline. In the sector (NACE 46), the median for financial year 2024 was 3 days before the deadline, and 39% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The financial year that closed on 30-06-2026 is due by 31-01-2027. Nothing is late today. The company usually files around 29 January (5 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
30-06-2026 year end04-11-2026 today31-01-2027 deadline
Financials
Financials · financial year 2025, full format
Annual accounts 2025 filed on 28-01-2026 PDF all 10 filings
Turnover
≈ €2.2m
Estimated: probably between €1.5m and €3.1m
EBIT margin
Not included in this filing
Net result
€128,641▼ 16.3%
2024 · €153,667
Working capital
€399,117▼ 4.2%
2024 · €416,811
Multi-year overview
2019 to 2025, 7 financial yearsOperating result
€168,304
▼ 19.5%
2025
20192025
Net result
€128,641
▼ 16.3%
2025
middle half of the sector
20192025
Equity
€500,272
▲ 1.8%
2025
middle half of the sector
20192025
Total assets
€3.2m
▲ 0.9%
2025
middle half of the sector
20192025
Debt
€2.7m
▲ 0.7%
2025
20192025
Working capital
€399,117
▼ 4.2%
2025
middle half of the sector
20192025
Solvency
15.8%
▲ 0.1pp
2025
lowest quarter of the sector
20192025
Current ratio
1.15
▼ 0.01
2025
lowest quarter of the sector
20192025
Return on assets (ROA)
4.1%
▼ 0.8pp
2025
middle half of the sector
20192025
Staff (FTE)
2.9
▲ 3.6%
2025
lowest quarter of the sector
20192025
Every figure per financial year
Every figure with its change against the financial year before
favourable
unfavourable
Line2019202020212022202320242025
Operating result€0.3m--€0.2m€0.4m€0.3m▼ 31.9%€0.2m▼ 15.8%€0.2m▼ 3.9%€0.2m▼ 19.5%
Net result€0.3m--€0.2mbelow the sector's middle half€0.4mwithin the sector's middle half€0.2mwithin the sector's middle half▼ 41.7%€0.2mwithin the sector's middle half▼ 20.7%€0.2mwithin the sector's middle half▼ 5.1%€0.1mwithin the sector's middle half▼ 16.3%
Equity€0.2m-€0.1mbelow the sector's middle half▼ 58.6%€0.3mwithin the sector's middle half▲ 226%€0.4mwithin the sector's middle half▲ 25.4%€0.5mwithin the sector's middle half▲ 10.1%€0.5mwithin the sector's middle half▲ 7.4%€0.5mwithin the sector's middle half▲ 1.8%
Total assets€1.5m-€1.8mwithin the sector's middle half▲ 20.2%€2.2mwithin the sector's middle half▲ 23.3%€2.4mwithin the sector's middle half▲ 10.9%€2.5mwithin the sector's middle half▲ 3.3%€3.1mwithin the sector's middle half▲ 25.9%€3.2mwithin the sector's middle half▲ 0.9%
Debt€1.2m-€1.7m▲ 35.9%€1.8m▲ 10.9%€2.0m▲ 8.3%€2.0m▲ 1.9%€2.6m▲ 30.1%€2.7m▲ 0.7%
Working capital€0.2m-€0.07mwithin the sector's middle half▼ 68.4%€0.3mwithin the sector's middle half▲ 303%€0.4mwithin the sector's middle half▲ 30.6%€0.4mwithin the sector's middle half▲ 10.4%€0.4mwithin the sector's middle half▼ 2.6%€0.4mwithin the sector's middle half▼ 4.2%
Solvency16.7%-5.8%below the sector's middle half▼ 10.9pp15.2%below the sector's middle half▲ 9.5pp17.2%below the sector's middle half▲ 2.0pp18.4%below the sector's middle half▲ 1.1pp15.7%below the sector's middle half▼ 2.7pp15.8%below the sector's middle half▲ 0.1pp
Current ratio1.19-1.04below the sector's middle half▼ 0.151.16within the sector's middle half▲ 0.121.20within the sector's middle half▲ 0.031.21within the sector's middle half▲ 0.021.16below the sector's middle half▼ 0.051.15below the sector's middle half▼ 0.01
Return on assets (ROA)18.0%--12.7%below the sector's middle half▼ 30.7pp16.1%above the sector's middle half▲ 28.7pp8.5%within the sector's middle half▼ 7.6pp6.5%within the sector's middle half▼ 2.0pp4.9%within the sector's middle half▼ 1.6pp4.1%within the sector's middle half▼ 0.8pp
Staff (FTE)1.9-3.4below the sector's middle half▲ 78.9%3.7within the sector's middle half▲ 8.8%3.8within the sector's middle half▲ 2.7%3.3below the sector's middle half▼ 13.2%2.8below the sector's middle half▼ 15.2%2.9below the sector's middle half▲ 3.6%
above
within
below
The sector band is the middle half of the companies in Wholesale trade (NACE 46). A quarter of them sit below it, a quarter above. Each year counts only accounts in the same format, and only where there are at least 30.
The operating result for 2025 is 20% lower than in 2024 and the lowest since 2021. It is the fourth fall in a row.
The turnover shown is an estimate from the gross margin.
Balance-sheet composition
2025 in colour, 2024 as the grey bar beneath
Assets €3.2m
Fixed assets
€101,155 ▲ 35.2%
Current assets
€3.1m ▲ 0.1%
Equity and liabilities €3.2m
Equity
€500,272 ▲ 1.8%
Debt
€2.7m ▲ 0.7%
Debt's share of the balance-sheet total falls from 84.3% to 84.2%. Equity and debt are higher.
Key figures and ratios
EBITDA
€187,285▼
2024 · €220,965
Cash flow
€147,623▼
2024 · €165,461
Quick ratio
0.86▲
2024 · 0.79
Debt to equity
5.34▼
2024 · 5.39
ROE
25.7%▼
2024 · 31.3%
Interest coverage
7.55▲
2024 · 5.99
Debt ≤ 1 year
€2.7m▲
2024 · €2.6m
Income taxes
€16,483▼
2024 · €19,063
Staff costs
€221,017▲
2024 · €196,501
Green means a favourable move, even when the figure itself falls, as with debt or debt to equity.
Staff
| Item | 30-06-2022 | 30-06-2023 | 30-06-2024 | 30-06-2025 |
|---|---|---|---|---|
| Employees at the balance-sheet date | 4 | 3 | 3 | 3 |
| full-time | 3 | 2 | 2 | 2 |
| part-time | 1 | 1 | 1 | 1 |
| in full-time equivalents | 3.8 | 2.8 | 2.8 | 2.8 |
| Average over the year, in full-time equivalents | 3.8 | 3.3 | 2.8 | 2.9 |
| On a permanent contract | 4 | 3 | 3 | 3 |
| Joined | 4 | 0 | 1 | 2 |
| Left | 4 | 1 | 1 | 2 |
Source: social balance sheet in the 2022 to 2025 annual accounts
Investments
| Item | 30-06-2022 | 30-06-2023 | 30-06-2024 | 30-06-2025 |
|---|---|---|---|---|
| Tangible fixed assets | €5,000 | €12,515 | €41,188 | €45,316 |
| Depreciation and write-downs of the year | €11,626 | €10,104 | €11,794 | €18,981 |
Source: notes to the 2022 to 2025 annual accounts (statement of fixed assets)
Annual accounts
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Remuneration, social security and pensions62 | - | - | - | €226,038 | €199,216 | €196,501 | €221,017 | ▲ 12.5% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets630 | €5,522 | €7,710 | €9,421 | €11,626 | €10,104 | €11,794 | €18,981 | ▲ 60.9% |
| Other operating charges640/8 | - | - | - | €26,883 | €9,974 | €2,386 | €26,253 | ▲ 11× |
| Gross operating margin9900 | €419,374 | €292,298 | €578,260 | €523,065 | €436,983 | €419,852 | €434,555 | ▲ 3.5% |
| Operating profit (loss)9901 | €273,673 | -€211,003 | €379,512 | €258,519 | €217,690 | €209,171 | €168,304 | ▼ 19.5% |
| Financial income75/76B | - | - | - | €6,071 | €5,038 | €473 | €1,623 | ▲ 243% |
| Recurring financial income75 | €3,272 | €7,421 | €245 | €6,071 | €5,038 | €473 | €1,623 | ▲ 243% |
| Financial charges65/66B | - | - | - | €24,089 | €37,825 | €36,914 | €24,803 | ▼ 32.8% |
| Recurring financial charges65 | €8,468 | €15,622 | €22,248 | €24,089 | €37,825 | €36,914 | €24,803 | ▼ 32.8% |
| Profit (loss) for the period before taxes9903 | €268,477 | -€219,205 | €357,509 | €240,501 | €184,903 | €172,730 | €145,124 | ▼ 16.0% |
| Income taxes67/77 | €3,773 | €4,498 | €7,401 | €36,277 | €22,953 | €19,063 | €16,483 | ▼ 13.5% |
| Profit (loss) for the period9904 | €264,704 | -€223,703 | €350,108 | €204,224 | €161,950 | €153,667 | €128,641 | ▼ 16.3% |
| Profit (loss) for the period to be appropriated9905 | €264,704 | -€223,703 | €350,108 | €204,224 | €161,950 | €153,667 | €128,641 | ▼ 16.3% |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Total assets20/58 | €1.5m | €1.8m | €2.2m | €2.4m | €2.5m | €3.1m | €3.2m | ▲ 0.9% |
| Fixed assets21/28 | €0.03m | €0.04m | €0.05m | €0.04m | €0.05m | €0.07m | €0.1m | ▲ 35.2% |
| Intangible fixed assets21 | €0 | €0 | €0.005m | €0.003m | €0.001m | - | - | - |
| Tangible fixed assets22/27 | €0.02m | €0.01m | €0.02m | €0.01m | €0.02m | €0.05m | €0.07m | ▲ 57.0% |
| Land and buildings22 | - | - | - | €0.003m | €0.002m | €0.001m | - | - |
| Plant, machinery and equipment23 | - | - | - | €0.006m | €0.009m | €0.03m | €0.05m | ▲ 32.0% |
| Furniture and vehicles24 | - | - | - | €0.004m | €0.005m | €0.01m | €0.03m | ▲ 143% |
| Financial fixed assets28 | €0.01m | €0.03m | €0.03m | €0.03m | €0.03m | €0.03m | €0.03m | = |
| Current assets29/58 | €1.4m | €1.7m | €2.1m | €2.4m | €2.4m | €3.1m | €3.1m | ▲ 0.1% |
| Stocks and contracts in progress3 | €0.2m | €0.4m | €0.9m | €0.4m | €0.6m | €1.0m | €0.8m | ▼ 20.4% |
| Stocks30/36 | - | - | - | €0.4m | €0.6m | €1.0m | €0.8m | ▼ 20.4% |
| Amounts receivable within one year40/41 | €0.7m | €1.1m | €1.2m | €1.9m | €1.8m | €1.8m | €2.0m | ▲ 12.5% |
| Trade receivables40 | - | - | - | €1.3m | €0.7m | €0.5m | €0.7m | ▲ 37.5% |
| Other amounts receivable41 | - | - | - | €0.6m | €1.1m | €1.3m | €1.3m | ▲ 2.1% |
| Cash at bank and in hand54/58 | €0.5m | €0.2m | €0.09m | €0.08m | €0.07m | €0.3m | €0.3m | ▼ 16.2% |
| Deferred charges and accrued income490/1 | - | - | - | €0.006m | €0.003m | - | €0.03m | - |
| Equity and liabilities | ||||||||
| Total equity and liabilities10/49 | €1.5m | €1.8m | €2.2m | €2.4m | €2.5m | €3.1m | €3.2m | ▲ 0.9% |
| Equity10/15 | €0.2m | €0.1m | €0.3m | €0.4m | €0.5m | €0.5m | €0.5m | ▲ 1.8% |
| Contributions10/11 | €0.02m | - | - | €0.1m | €0.1m | €0.1m | €0.1m | = |
| Reserves13 | €0.04m | €0.04m | €0.04m | €0.04m | €0.04m | €0.04m | €0.04m | = |
| Distributable reserves133 | - | - | - | €0.04m | €0.04m | €0.04m | €0.04m | = |
| Profit (loss) carried forward14 | €0.2m | -€0.04m | €0.2m | €0.3m | €0.3m | €0.4m | €0.4m | ▲ 2.4% |
| Amounts payable17/49 | €1.2m | €1.7m | €1.8m | €2.0m | €2.0m | €2.6m | €2.7m | ▲ 0.7% |
| Amounts payable within one year42/48 | €1.2m | €1.6m | €1.8m | €2.0m | €2.0m | €2.6m | €2.7m | ▲ 0.7% |
| Current portion of amounts payable after more than one year42 | - | - | - | - | €0.005m | - | €0.01m | - |
| Financial debts43 | - | - | - | €0.5m | €0.5m | €0.5m | €0.7m | ▲ 39.6% |
| Credit institutions430/8 | - | - | - | €0.5m | €0.5m | €0.5m | €0.7m | ▲ 39.6% |
| Trade debts44 | €0.8m | €1.0m | €1.0m | €1.2m | €1.2m | €1.9m | €1.7m | ▼ 9.6% |
| Suppliers440/4 | - | - | - | €1.2m | €1.2m | €1.9m | €1.7m | ▼ 9.6% |
| Advances received on contracts in progress46 | - | - | - | €0.01m | €0.01m | €0.01m | - | - |
| Taxes, remuneration and social security45 | - | - | - | €0.04m | €0.02m | €0.02m | €0.02m | ▲ 18.1% |
| Taxes450/3 | - | - | - | €0.01m | €208 | €70 | €70 | = |
| Remuneration and social security454/9 | - | - | - | €0.03m | €0.02m | €0.02m | €0.02m | ▲ 18.1% |
| Other amounts payable47/48 | - | - | - | €0.3m | €0.3m | €0.3m | €0.2m | ▼ 1.9% |
| Accrued charges and deferred income492/3 | - | - | - | €0.02m | €0.02m | - | - | - |
| Line | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Change |
|---|---|---|---|---|---|---|---|---|
| Profit (loss) for the period9904 | €264,704 | -€223,703 | €350,108 | €204,224 | €161,950 | €153,667 | €128,641 | ▼ 16.3% |
| + Depreciation and write-downs630 | €5,522 | €7,710 | €9,421 | €11,626 | €10,104 | €11,794 | €18,981 | ▲ 60.9% |
| Operating cash flow (approximation) | €270,226 | -€215,993 | €359,530 | €215,850 | €172,054 | €165,461 | €147,623 | ▼ 10.8% |
| Investment in fixed assets (approximation) | - | -€23,161 | -€16,652 | -€5,000 | -€12,515 | -€40,593 | -€45,316 | ▼ 11.6% |
| Change in cash | - | -€240,720 | -€142,799 | -€6,714 | -€5,160 | €245,435 | -€51,857 | - |
A Belgian filing has no cash-flow statement. These rows are therefore an approximation, derived from the income statement and the balance-sheet moves.
Historical observation
In July 2024, 4,508 companies had the same profile as IC PHARMA has now. Two years later, 96.9% were still going and 1.4% had gone bankrupt.
- Micro
- 10 to 20 years old
- solvency 10 to 30%
- a profit under 5% of the balance sheet
96.9%
was still going
1.6%
stopped otherwise
1.4%
went bankrupt
That fits the bankruptcy probability of IC PHARMA itself: 0.3% within 12 months.
Test of the method
The method was tested on the 497,446 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 4,508 companies, not a prediction for IC PHARMA. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Filings with the National Bank (10)
| Financial year | Type | Filed | Reference | Document |
|---|---|---|---|---|
| 30-06-2025 | full format | 28-01-2026 | 2026-00015539 | |
| 30-06-2024 | full format | 28-02-2025 | 2025-00040701 | |
| 30-06-2023 | full format | 29-01-2024 | 2024-00009032 | |
| 30-06-2022 | full format | 13-02-2023 | 2023-00026633 | |
| 30-06-2021 | full format | 30-12-2021 | 2021-82000597 | |
| 30-06-2020 | full format | 28-02-2021 | 2021-06300504 | |
| 30-06-2019 | full format | 30-01-2020 | 2020-02800018 | |
| 30-06-2018 | full format | 25-01-2019 | 2019-02100581 | |
| 30-06-2017 | full format | 28-12-2017 | 2017-73100588 | |
| 30-06-2016 | abbreviated format | 21-12-2016 | 2016-71200230 |
Board & ownership
Directors
Directors
2 directors
INTERCONCEPT SRL
Current
Director · since 10-10-2019 · Legal entity · listed in the 2025 annual accounts, filed on 28-01-2026
LE GALL Tangie
Current
Owners and capital
Shareholders
1 ownerChain of control
- INTERCONCEPT
- IC PHARMA
Owners 1
- INTERCONCEPTparentEquity €1.3m Loss of €87,185 in 2025 (profit of €88,253 in 2024) Checked score 8498.92%
Mandate history
2 people, 2 in office
- Board
| Name | Functions and periods |
|---|---|
| INTERCONCEPT SRL |
|
| LE GALL Tangie |
|
Network & group
Holdings and subsidiaries
3 holdingsHoldings 3
Source for every holding own accounts 30-06-2025
- IC PHARMA VIETNAMVNsubsidiary90%
- SILVERSTONE SCIFREquity -€180,712Result -€37,93610%
- Equity €38,779 Profit of €11,659 in 2025 (profit of €48,576 in 2024) Checked score 700.27%
Companies at the same address
4 other companiesConnections & network
2 current directorsThe network starts from the directors of IC PHARMA. Every other company they run is a node.
This company
Company
Director
Shareholding
+N: links not shown yet
Click a node to look further, drag to arrange, zoom with the mouse wheel.
Timeline
Acts, filings and financial milestones
Deadline for the 2026 accounts:
2026
28-01
full format · 3 days before the deadline
2025
30-06
Financial
Equity above €500,000equity €500,272 ▲1.8%
After 5 profitable years in a row, equity reaches €500,272.
28-02
full format · 28 days late
2024
18-06
Gazette deed
Registered office moved from Bruxelles to TubizeNew seat: rue François Englert 10 à 1480 Tubize · Previous seat: rue du Congrès 35 à 1000 Bruxelles2 points ▸
Gazette deed
Registered office moved from Bruxelles to Tubize
New seat: rue François Englert 10 à 1480 Tubize · Previous seat: rue du Congrès 35 à 1000 Bruxelles2 points ▸
- General meeting, 07-04-2024
- Registered-office move, rue François Englert 10 à 1480 Tubize
29-01
full format · 2 days before the deadline
2023
13-02
full format · 13 days late
2021
30-12
full format · 32 days before the deadline
22-09
Gazette deed
Registered office moved from Watermael-Boitsfort to BruxellesNew seat: rue du Congrès 35 à 1000 Bruxelles · Previous seat: Chaussée de la Hulpe 177/20 à 1170 Watermael-Boitsfort · Permanent representative: Van Hamme Jean-Baptiste4 points ▸
Gazette deed
Registered office moved from Watermael-Boitsfort to Bruxelles
New seat: rue du Congrès 35 à 1000 Bruxelles · Previous seat: Chaussée de la Hulpe 177/20 à 1170 Watermael-Boitsfort · Permanent representative: Van Hamme Jean-Baptiste4 points ▸
- General meeting, 20-04-2021
- Registered-office move, rue du Congrès 35 à 1000 Bruxelles
- Director in office, INTERCONCEPT (director)
- Permanent representative, Van Hamme Jean-Baptiste
30-06
Financial
Back to profitnet €350,108
The net result is €350,108, after one loss-making year.
30-06
Financial
Equity above €200,000equity €331,790 ▲226%
Equity rises from €101,682 to €331,790.
28-02
full format · 28 days late
2020
30-06
Financial
Weakest financial yearnet -€223,703
The net result drops to -€223,703, the lowest from 2019 to 2025. It recovers the following year.
Show earlier events
30-01
full format · 1 day before the deadline
2019
25-01
full format · 6 days before the deadline
2017
28-12
full format · 34 days before the deadline
2016
21-12
abbreviated format · 41 days before the deadline
2014
28-11
Financial milestoneGazette deedNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
Sources:Publications in the Belgian Official GazetteFilings with the National Bank
History
Company details
Register details
Identity
KBO recordName
IC PHARMA in French
Enterprise number
0505.707.124
LEI code
894500BCBWOT3Q0Q6K84
no longer live in the LEI register
Legal form
Private limited company
Status
Active, normale toestand
Founded
26-11-2014
Entity type
Legal entity
Registered office and establishments
Registered office
Rue François Englert 10, 1480 Tubize, Belgium
2 former offices
- rue du Congrès 35, 1000 Bruxelles until 01-05-2024 · act of 18-06-2024
- Chaussée de la Hulpe 177/20, 1170 Watermael-Boitsfort until 01-04-2021 · act of 22-09-2021
Establishment unit
Rue François Englert 10, 1480 Tubize since 01-05-2024 · unit number 2.359.997.627
Activities
NACEBEL 2025VAT activities
46460
Wholesale of pharmaceutical and medical goods main activity
Social security (RSZ) activities
46460
Wholesale of pharmaceutical and medical goods main activity
Codes under NACEBEL 2008
VAT activities
46460
Wholesale trade main activity
Social security (RSZ) activities
46460
Wholesale trade main activity
Joint committee
200 Aanvullend Paritair Comité voor de bedienden annual accounts 30-06-2024
Invoicing and payment
VAT number
BE 0505.707.124
Financial year and general meeting
Accounts at the NBBFinancial year end
30-06
Sites & property
Location
Buildings and parcels at the address
Ground area
3,243 m²
| Cadastral parcel | Region | Area | Buildings | Height / floors |
|---|---|---|---|---|
| 25105A0528/00B000 | Wallonia | 3,243 m² | - | - |